Core Viewpoint - The article discusses the investment potential of Novo Nordisk (NVO), highlighting a base-case fair value estimate of $83 based on peer comparison, a Discounted Dividend Model (DDM), and a Discounted Cash Flow (DCF) analysis [1] Group 1 - The author first covered Novo Nordisk in mid-May when the stock price was approximately $65 [1] - The investment strategy combines fundamental analysis with options trading, focusing on various strategies including income-oriented investments, growth at a reasonable price, deep value, and dividend aristocrats [1] - The author has a long position in Novo Nordisk shares through stock ownership, options, or other derivatives [2]

Core Insights - Avista Corporation (NYSE: AVA) was initially covered in October last year with a "Buy" rating at approximately $38, and a Fair Value estimate of $43.07 based on a Discounted Dividend Model (DDM) [1] Group 1: Investment Strategy - The investment strategy combines fundamental analysis with options trading, focusing on various strategies including income-oriented investments, growth at a reasonable price, deep value, and dividend aristocrats [1] - The analyst employs 20-25 options strategies for purposes such as hedging, bullish substitutes, neutral trades, trading volatility, and earnings-related trades [1] Group 2: Background and Expertise - The analyst has a background in software development and has experience in teaching and coaching in various areas, including investing [1]